Dipen P. Sangurdekar

TRACE identifies tumor-reactive CD8+ T cells across solid tumors using clonotype-level classification and scRNA-seq data, showing high accuracy and specificity for tumor-experienced T cells.

This study identifies Regnase-1 and SOCS1 dual-inactivation as a strategy to enhance anti-tumor functionality of CD8+ T cells by rewiring their differentiation and effector state.

This study predicts HRD in 1,332 cancer and 84 non-cancer cell lines using CHORD and HRDsum, finding BRCA1/2 mutations and epigenetic silencing as key predictors.